DDReg Pharma- Consulting in regulatory affairs and drug safety

  The rules governing the clinical trials in the UK have not seen a change of this scale since 2004. With the UK Clinical Trials Amendment Regulations 2025 coming into force, sponsors need to take immediate steps to ensure compliance before April 2026.   These amendments are not simply administrative paperwork – they impact clinical trial design, safety monitoring, data management, and regulatory reporting. Lack of compliance can trigger approval of postponements, regulatory challenges, or trial suspension.   We are breaking down the key changes, outlining sponsor responsibilities, and providing actionable steps to help organizations maintain a competitive edge.   Why the UK Clinical Trials Amendment Regulations 2025 Matter? The UK’s new Clinical Trials Regulation 2025 marks a modernized shift to renew UK trial activity and reinforce its position in global research. The MHRA aims to create a framework that prioritizes...

 In the pharmaceutical world, a drug’s journey doesn’t end when it hits the pharmacy shelf. In fact, for Pharmacovigilance (PV) experts , that is where the most critical work begins. The Pharmacovigilance lifecycle is a continuous, circular process designed to monitor a medicine’s safety profile from its earliest clinical trials until the day it is discontinued. Here is a breakdown of the stages that keep patients safe worldwide. Phase 1: Pre-Marketing (The Clinical Trial Phase) Before a drug is available to the public, it undergoes rigorous testing. In this stage, PV is focused on safety data collection from controlled environments. The Goal: Identify common side effects and establish a "baseline" safety profile. Key Activity: Serious Adverse Events (SAEs) must be reported to regulators within strict timelines (often 7 to 15 days). Phase 2: Signal Detection (The "Listening" Phase) Once the drug is approved and used by thousands (or millions) of people, PV enter...

  2026 is shaping up to be a transformative year for pharmacovigilance in the European Union and at the heart of this change is a comprehensive overhaul of the European Medicines Agency’s (EMA) Good Pharmacovigilance Practices (GVP) framework. This isn’t just regulatory housekeeping; it’s a smart modernisation of how drug safety is monitored, analysed, and communicated across the EU. What’s Changing and Why It Matters The EMA has signalled that almost all GVP modules are scheduled for revision in 2026 , spanning core areas such as signal management, risk management plans, inspections, individual case safety reports (ICSRs), and post-authorisation safety studies. These updates are part of a wider push to ensure pharmacovigilance keeps pace with scientific, technological, and data-driven advances in medicine. Key trends emerging from the GVP update schedule include: 🔹 Modernised Signal Detection and Management- Modules such as GVP IX are being updated to reflect more integrate...